MedTrace Logo

Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

NCT06218342 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2024-01-23

No results posted yet for this study

Summary

This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.

Conditions

Interventions

DRUG

Henagliflozin

Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.

OTHER

Background medication

Participants will only receive lifestyle intervention and background medication.

Sponsors & Collaborators

  • Sir Run Run Shaw Hospital

    lead OTHER

Principal Investigators

  • Jiaqiang Zhou · Sir Run Run Shaw Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-12-31
Completion
2025-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06218342 on ClinicalTrials.gov